Singapore, Aug. 10 -- AuctuCel, a Singapore-based biotechnology company specialising in AI-powered bioprocess technologies, has announced the launch of AuctuPrime, a next-generation chemically defined cell culture medium developed in collaboration with China-based Sperikon.

The formulation is designed to remove dependence on both animal serum and donor-derived human platelet supplements during cell therapy manufacturing.The launch comes as markets continue to deepen their advanced therapy ecosystems. The Singapore Economic Development Board reported that the country saw a fourfold increase in locally incorporated biotechnology companies since 2015.

In Malaysia, the National Pharmaceutical Regulatory Agency issued updated cell and gene t...